MREO
Mereo BioPharma Group plc (MREO) 10Y Growth Potential Analysis (2026)
Overall Score
Profitability
Margins remain effectively zero, with TTM gross, operating, EBITDA, pretax, and net profit margins all at 0.0.
Returns are still deeply negative, including ROA of -0.81, ROE of -0.75, and ROIC of -1.13.
Growth
Fresh metrics do not show revenue or earnings growth support, with revenue per share still at 0 and profitability remaining negative.
No recent news indicates a new commercial catalyst or demand inflection.
Financial Health
Liquidity remains strong with a current ratio of 5.88 and cash ratio of 5.31.
Balance-sheet leverage is low, with debt-to-equity at 0.036 and debt-to-assets at 0.030, though solvency and coverage metrics remain distorted by negative operating earnings.
Valuation
The company still screens as asset-backed rather than earnings-backed, with price-to-book at 1.75 and tangible book value per share near 0.18.
Negative earnings and cash flow keep traditional earnings and cash-flow multiples non-informative, limiting valuation confidence.
Momentum
No fresh news or operating data suggests a momentum improvement this month.
The business remains unprofitable, which continues to weigh on sentiment and share-price support.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Mereo BioPharma Group plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

